for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

CohBar Inc

CWBR.OQ

Latest Trade

1.43USD

Change

0.08(+5.93%)

Volume

1,343

Today's Range

1.36

 - 

1.49

52 Week Range

1.11

 - 

4.40

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.35
Open
1.36
Volume
1,343
3M AVG Volume
0.68
Today's High
1.49
Today's Low
1.36
52 Week High
4.40
52 Week Low
1.11
Shares Out (MIL)
42.86
Market Cap (MIL)
56.15
Forward P/E
--
Dividend (Yield %)
--

Next Event

CohBar Inc at Biotechnology Industry Organization (BIO) Investor Forum Conference

Latest Developments

More

Cohbar Q2 Loss Per Share $0.07

Cohbar Q1 Loss Per Share $0.07

CohBar Appoints Steven Engle As CEO

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About CohBar Inc

CohBar, Inc. (CohBar) is engaged in the research and development of mitochondria-based therapeutics (MBTs), a class of drugs with potential for the treatment of diseases associated with aging. MBTs originate from the discovery of a group of peptides encoded within the genome of mitochondria. The Company's development of mitochondrial-derived peptides (MDPs) into MBTs offers the potential to address a range of diseases including type 2 diabetes, cancer, atherosclerosis and neurodegenerative disorders. MDPs represent a diverse and largely unexplored collection of peptides. MOTS-c is an MDP, which indicates that it plays a role in the regulation of metabolism. The Company is engaged in the research on MOTS-c and its analogs as its lead program. The Company's academic collaborators have discovered various other MDPs with similar mitochondrial origin to the MDP, humanin, which the Company refers to as small humanin-like peptides (SHLPs).

Industry

Biotechnology & Drugs

Contact Info

1455 Adams Dr Ste 2050

+1.650.4467888

https://www.cohbar.com/

Executive Leadership

Albion J. Fitzgerald

Independent Chairman of the Board

Steven B. Engle

Chief Executive Officer, Director

Jeffrey Francis Biunno

Chief Financial Officer, Treasurer, Secretary

Jon Leland Stern

Chief Operating Officer, Director

Kenneth C. Cundy

Chief Scientific Officer

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
4.09
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
22.82
LT Debt To Equity (MRQ)
22.82
Return on Investment (TTM)
-67.78
Return on Equity (TTM)
-63.64

Latest News

Latest News

BRIEF-CohBar Reports Q4 Loss Per Share $0.07

* COHBAR, INC. ANNOUNCES FOURTH QUARTER 2017 FINANCIAL RESULTS

BRIEF-Cohbar, Inc. Announces Financing Of Up To Us$5,000,000 In Unsecured Promissory Notes

* COHBAR, INC. ANNOUNCES FINANCING OF UP TO US$5,000,000 IN UNSECURED PROMISSORY NOTES

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up